Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance
Recent Deal Brought In Bioeq’s Lucentis Biosimilar In Europe
Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.
